VitriVax Raises $87 Million To Advance Lyme Disease Vaccine

VitriVax has closed an oversubscribed $87 million Series C to move its Lyme disease vaccine candidate into a first-in-human clinical trial and expand its proprietary vaccine pipeline. F-Prime, NEA, RA Capital Management, and Sanofi Ventures co-led the round. Eli Lilly and existing investors also participated.

Single-Dose Vaccine Platform

VitriVax is developing its pipeline around the Atomic Layering Thermostable Antigen and Adjuvant platform.

The technology is designed to enable single-dose vaccines, improve immune responses, reduce the quantities of antigen and adjuvant required, and decrease dependence on refrigerated distribution. VitriVax has also applied the platform to mRNA delivery without lipid nanoparticles.

Its lead candidate is designed to provide broad protection against Lyme disease through a new mechanism. There is currently no approved human vaccine for Lyme disease, while other candidates in development require multiple initial doses and seasonal boosters.

The company will use the financing to generate initial clinical data and develop additional wholly owned programs.

VitriVax previously raised a $17.25 million Series B and has received support from the Gates Foundation, CEPI, and the U.S. Department of Defense.

KEY QUOTES:

The strong demand for this financing round and the caliber of investors who joined it reflect growing conviction in our ALTA platform and in our Lyme disease vaccine candidate. This financing marks VitriVax’s transition into a vaccine development company with its own pipeline. Our priorities now are to generate first-in-human data for our Lyme disease candidate, and build a portfolio of proprietary programs, while continuing our work with global health partners to bring better vaccines to the people who need them most.

Romulo Colindres, CEO of VitriVax

We believe innovation in vaccine development and delivery has the potential to improve how vaccines are designed, manufactured, and ultimately used. VitriVax’s ALTA platform brings together several compelling capabilities into one differentiated approach, and we are excited to support the team as they advance the technology and explore its potential across a broader range of applications.

Chris Gagliardi, Principal at Sanofi Ventures

We need a safe, effective, and convenient Lyme vaccine to prevent millions of people from suffering the dangerous, chronic, and painful ramifications of this increasingly common disease. We are proud to continue to support Vitrivax as it advances this unique program and continues to develop its ALTA platform, a potentially game-changing technology across protein/glycoconjugate and mRNA modalities.

Mario Barro, Head of Infectious Diseases and Venture Partner at RA Capital

Vaccines have the power to truly impact lives when they are accessible and easy to use in real-world settings. VitriVax’s approach eliminates traditional barriers – complex dosing and cold chain hurdles – so more people can benefit. We are proud to support VitriVax as they advance practical solutions for patients and healthcare providers alike.

Muzammil Mansuri, Venture Partner at F-Prime